Charles Schoch is CFO at Candel Therapeutics, Inc. (CADL). They have made 4 open-market trades across 1 company since 2024, most recently 2025-06-25.
CIK 0002007349
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CADL | 43,391 | $355K |
Shares reported on the most recent Form 4, priced at the 2025-06-26 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CADL | SELL · 10b5-1 | 2025-03-17 | 2025-03-19 | $8.83 | $44K | -36.9% | -49.6% | -44.8% |
| CADL | SELL | 2025-01-15 | 2025-01-17 | $7.23 | $138K | +2.1% | +39.6% | -33.0% |
| CADL | SELL | 2025-01-08 | 2025-01-10 | $8.22 | $164K | -13.1% | +6.8% | -41.3% |
| CADL | SELL | 2024-07-17 | 2024-07-19 | $6.47 | $128K | -1.3% | -12.6% | -2.3% |
| CADL | SELL | 2024-07-11 | 2024-07-15 | $5.97 | $106K | -1.5% | -20.4% | -9.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.